

## Format for ANSWERING REVIEWERS

October 8, 2014



Dear Editor:

Please find enclosed the edited manuscript in Word format (file name: 13073-review.doc).

**Title:** Recent Advances in the HER2 Targeted Therapy of Gastric Cancer

**Authors:** Tasuku Matsuoka and Masakazu Yahsiro

**Name of Journal:** *World Journal of Clinical Cases*

**ESPS Manuscript NO:** 13073

The manuscript has been improved (highlighted in yellow) according to the suggestions of reviewers. We modified carefully our manuscript to avoid overlapping.

1 Format has been updated

2 Revision has been made according to the suggestions of the reviewer

(1) **02456031**

I think the paper is a well written and comprehensive state-of-the-art review on HER2 targeted therapy in gastric cancer. I have some suggestion which might help improving the quality of the paper.

Table 1. Study design: please, add information on the full study design (randomized, double-blind, parallel group, cross-over, controlled, etc.). Also add information on the duration of treatment (e.g. weeks or number of cycles, etc.)

*Response: Thank you for the kind suggestions. We appreciate the reviewer's comments. As the reviewer mentioned, we have modified Table 1 by adding full study design and duration of treatment by referring the Clinical Trials. gov as possible.*

Table 2. Which is the meaning and usefulness of referring to the PMID? Please, remove this reference from the table.

*Response: We have removed the section of PMID as the reviewer pointed out.*

Conclusion and future prospects (may be "perspectives" is a better term). I would try to summarize a bit the final message. Likely, a bullet point table would help. Please, send a clear and practical message to the reader.

*Response: We changed the discussion to be more specific,*

Please, revise the English style. There are some spelling and grammatical errors, here and there. e.g. Page 4 "is belongs". Page 7 "the utilizing...". Page 14 "TRSTUZUMAB". Table 1 "preoprative".

*Response: We apologize for the careless mistakes. The entire manuscript has been carefully rewritten to correct English grammar and spelling and to make the manuscript as clear as possible.*

(2) **02439561**

You did good jobs to review about target therapy for gastric cancer, which are currently hot issues.

However, you need to review with time before submission your manuscript.

*Response: Thank you for the reviewer's comment. We asked one of my clinical co-workers who has a great knowledge of chemotherapy including trastuzumab to review our manuscript. He gave us several effective suggestions which were reflected in our manuscript.*

(3) 02454257

With this manuscript the authors present a commendable task requiring great diligence on the current status of HER2 targeted therapy of gastric cancer. The considerable data is the first problem of this manuscript. It is definitely too extensive for an overview article. This manuscript does have the potential for a book chapter which is supported by the large number of 89(!) references. Furthermore, there has been a large number of publications including reviews within the last year focusing on new therapy possibilities of gastric cancer via the HER2 pathway (see especially BPG, Jørgensen JT, 2014). This is the reason why the novelty effect compared to the complexity of the manuscript is small. In my opinion the authors should focus either on the experimental results with cell lines and tumor specimen or on the clinical study data.

*Response: We appreciate your helpful comments on our manuscript. According to your comments, we focused our data into the clinical trial, except the minimally required experimental data, which were essential to keep the theme of this review, to enhance the specificity of our manuscript. We omitted Table 2. We carefully read the literature you recommended, and were pleased to cite this paper.*

Independents of the above the authors should put more value judgment in the conclusion and future prospects section. General statements like: "...These data will provide a rationale for developing more potent HER2 inhibitors...." do only marginally live up to the scientific demands of the authors. In the presented very extensive form the manuscript does provide insufficient new information and is therefore not suitable for publication in the World Journal of Clinical Cases.

*Response: We really appreciate your helpful comments. As you commented, we revised our conclusion to be more specific and of more interest to the readers.*

(4) 02460781

This review is on the recent advances in the HER2 targeted therapy of gastric cancer. It is a well-written article. I recommend acceptance for publication. And I have a suggestion, it will be better if the author can add the number of the patients in each study in table one "Table 1. Clinical trials of HER2-targeted therapy in gastric cancer (after ToGA study)

*Response: We appreciate your helpful comments. According to your comments, we added the number of patients in Table 1.*

(5) 00058511

It is a well-written comprehensive review article on the novel biological agents opening new horizons and research efforts with promising results for gastric cancer. With great pleasure I recommend acceptance for publication.

*Response: We really appreciate your comments.*

3 References and typesetting were corrected

Thank you again for publishing our manuscript in the *World Journal of Clinical Cases*

Sincerely yours

Yashiro Masakazus

Masakazu Yashiro, MD, PhD

Department of Surgical Oncology, Osaka City University Graduate School of Medicine,  
1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan

TEL; (+81) 6-6645-3838

FAX; (+81) 6-6646-6450

e-mail address; m9312510@med.osaka-cu.ac.jp